{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:57:30Z","timestamp":1789088250115,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vaccine.2022.10.031","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T18:40:23Z","timestamp":1667328023000},"page":"7176-7181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Estimating the population level impact of a gonococcal vaccine candidate: Predictions from a simple mathematical model"],"prefix":"10.1016","volume":"40","author":[{"given":"Kelly A.","family":"Carey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori M.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"Spicknall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.10.031_b0005","unstructured":"Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2019. Atlanta; 2021. [Online]. Available from: https\/\/www.cdc.gov\/std\/statistics\/2019\/default.htm."},{"key":"10.1016\/j.vaccine.2022.10.031_b0010","unstructured":"Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States 2019. Atlanta; 2019. [Online]. Available from: https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf."},{"key":"10.1016\/j.vaccine.2022.10.031_b0015","unstructured":"U.S. Department of Health and Human Services. Sexually transmitted infections national strategic plan for the United States: 2021\u20132025. Washington D.C.; 2020. [Online]. Available from: https:\/\/www.hhs.gov\/sites\/default\/files\/STI-National-Strategic-Plan-2021-2025.pdf."},{"issue":"5","key":"10.1016\/j.vaccine.2022.10.031_b0020","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1071\/SH19060","article-title":"Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap","volume":"16","author":"Gottlieb","year":"2019","journal-title":"Sexual Health"},{"key":"10.1016\/j.vaccine.2022.10.031_b0025","doi-asserted-by":"crossref","unstructured":"Russell MW, Jerse AE, Gray-Owen SD. Progress toward a gonococcal vaccine: the way forward. Front Immunol 10;2019. Frontiers Media S.A. doi: 10.3389\/fimmu.2019.02417.","DOI":"10.3389\/fimmu.2019.02417"},{"issue":"10102","key":"10.1016\/j.vaccine.2022.10.031_b0030","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.10.031_b0035","unstructured":"P\u00e9rez O, Cuello M, Gonz\u00e1lez E. Mucosal approaches in Neisseria Vaccinology. Accessed: May 07, 2021. [Online]. Available from: https:\/\/www.researchgate.net\/publication\/26636153."},{"key":"10.1016\/j.vaccine.2022.10.031_b0040","doi-asserted-by":"crossref","unstructured":"Whelan J, Kl\u00f8vstad H, Haugen IL, Robert-Du Ry van Beest Holle M, Storsaeter J. Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection. Norway. Emerg Infect Dis 22(6);2016:1137\u20139. Centers for Disease Control and Prevention (CDC). doi: 10.3201\/eid2206.151093.","DOI":"10.3201\/eid2206.151093"},{"issue":"33","key":"10.1016\/j.vaccine.2022.10.031_b0045","doi-asserted-by":"crossref","first-page":"718","DOI":"10.15585\/mmwr.mm6833a2","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years \u2014 United States, 2018","volume":"68","author":"Walker","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"19","key":"10.1016\/j.vaccine.2022.10.031_b0050","doi-asserted-by":"crossref","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","article-title":"Updated recommendations for use of MenB-FHbp Serogroup B meningococcal vaccine \u2014 advisory committee on immunization practices, 2016","volume":"66","author":"Patton","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"36","key":"10.1016\/j.vaccine.2022.10.031_b0055","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1016\/j.vaccine.2017.07.056","article-title":"Emerging clinical experience with vaccines against group B meningococcal disease","volume":"36","author":"Wilkins","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.10.031_b0060","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine bexsero elicits antibodies to Neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"36","key":"10.1016\/j.vaccine.2022.10.031_b0065","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1016\/j.vaccine.2015.07.015","article-title":"The potential impact of vaccination on the prevalence of gonorrhea","volume":"33","author":"Craig","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.10.031_b0070","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.4161\/hv.36221","article-title":"Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: Results from a decision-analysis model","volume":"10","author":"R\u00e9gnier","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2022.10.031_b0075","doi-asserted-by":"crossref","unstructured":"Seedat S, Abu-Raddad L. P653 Modeling the impact of partially efficacious gonorrhea vaccines. In: Sexually Transmitted Infections, Jul. 2019, vol. 95, no. Suppl 1. p. A288.1\u2013A288. doi: 10.1136\/sextrans-2019-sti.721.","DOI":"10.1136\/sextrans-2019-sti.721"},{"key":"10.1016\/j.vaccine.2022.10.031_b0080","doi-asserted-by":"crossref","unstructured":"Heijne J, Xiridou M, Turner K, Van Benthem B, Low N. P505 The impact of gonorrhoea vaccination in men who have sex with men on prevalence and resistance: mathematical modelling study. In: Sexually Transmitted Infections, Jul. 2019, vol. 95, no. Suppl 1. p. A232.2\u2013A232. doi: 10.1136\/sextrans-2019-sti.585.","DOI":"10.1136\/sextrans-2019-sti.585"},{"issue":"8","key":"10.1016\/j.vaccine.2022.10.031_b0085","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/cid\/ciz1241","article-title":"Assessment of the potential of vaccination to combat antibiotic resistance in Gonorrhea: a modeling analysis to determine preferred product characteristics","volume":"71","author":"Whittles","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.031_b0090","unstructured":"U.S. Department of Health and Human Services. Reduce gonorrhea rates in male adolescents and young men \u2014 STI\u201102. Health People 2030, 2020. Available from: https:\/\/health.gov\/healthypeople\/objectives-and-data\/browse-objectives\/sexually-transmitted-infections\/reduce-gonorrhea-rates-male-adolescents-and-young-men-sti-02."},{"issue":"3","key":"10.1016\/j.vaccine.2022.10.031_b0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/OLQ.0b013e318286bb53","article-title":"Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008","volume":"40","author":"Satterwhite","year":"2013","journal-title":"Sex Transm Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.10.031_b0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/OLQ.0000000000001382","article-title":"Estimates of the prevalence and incidence of Chlamydia and Gonorrhea among US Men and Women, 2018","volume":"48","author":"Kreisel","year":"2021","journal-title":"Sex Transm Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.10.031_b0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/OLQ.0000000000000953","article-title":"Assessing uncertainty in an anatomical site-specific gonorrhea transmission model of men who have sex with men","volume":"46","author":"Spicknall","year":"2019","journal-title":"Sex Transm Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2022.10.031_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22012919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22012919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:21:56Z","timestamp":1759404116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22012919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":22,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0264410X22012919"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating the population level impact of a gonococcal vaccine candidate: Predictions from a simple mathematical model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}